BRAFV600E detection in melanoma is highly improved by COLD-PCR.
暂无分享,去创建一个
V. de Giorgi | D. Massi | M. Pazzagli | Claudio Santucci | I. Mancini | C. Orlando | P. Pinzani | L. Simi | F. Salvianti | Nicola Pratesi
[1] K. Flaherty,et al. Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Kefford,et al. Targeting BRAF for patients with melanoma , 2010, British Journal of Cancer.
[3] D. Allingham-Hawkins,et al. BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer , 2010, PLoS currents.
[4] C. Wellbrock,et al. BRAF as therapeutic target in melanoma. , 2010, Biochemical pharmacology.
[5] F. Hodi,et al. Advances in targeted therapy for melanoma. , 2010, Clinical advances in hematology & oncology : H&O.
[6] F. Cianchi,et al. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. , 2010, The Journal of molecular diagnostics : JMD.
[7] Michael Krauthammer,et al. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells , 2010, Pigment cell & melanoma research.
[8] Yuri E Nikiforov,et al. Molecular diagnostics and predictors in thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[9] Cheng Li,et al. Two‐round coamplification at lower denaturation temperature–PCR (COLD‐PCR)‐based sanger sequencing identifies a novel spectrum of low‐level mutations in lung adenocarcinoma , 2009, Human mutation.
[10] H. Koeppen,et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples , 2009, Modern Pathology.
[11] F. Cianchi,et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. , 2008, American journal of clinical pathology.
[12] R. Berbeco,et al. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing , 2008, Nature Medicine.
[13] P. Gimotty,et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. , 2007, The Journal of molecular diagnostics : JMD.
[14] S. O’Day,et al. Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy , 2007, Clinical Cancer Research.
[15] M. Trivett,et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.
[16] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[17] P. Khavari,et al. Melanoma genetics and the development of rational therapeutics. , 2005, The Journal of clinical investigation.
[18] D. Polsky,et al. Clinical significance of BRAF mutations in metastatic melanoma , 2004, Journal of Translational Medicine.
[19] C. Marshall,et al. B-RAF is a therapeutic target in melanoma , 2004, Oncogene.
[20] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[21] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[22] U. Lehmann,et al. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. , 2000, The American journal of pathology.